《睡眠專業人士雜誌》
星期五, 七月 24, 2026
Nox Health has acquired Somryst, the first FDA-cleared Prescription Digital Therapeutic (PDT) that delivers effective, first-line treatment for adults with chronic insomnia. This acquisition deepens the Nox value-based healthcare programs, as it seeks to reframe sleep as a critical and powerful intervention strategy for chronic health conditions management. “The acquisition […]
Pear Therapeutics, Inc., announced the availability of Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia. Somryst addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), an evidence-based approach […]
六月 features the shortest nights of the year, but for those living with chronic insomnia, every night is long. That’s why the American Academy of Sleep Medicine (AASM), Society of Behavioral Sleep Medicine (SBSM) and American Alliance for Healthy Sleep (AAHS) are working to raise awareness of the disease with Insomnia Awareness Night […]
Preliminary findings from two analyses of an ongoing study suggest that cognitive behavioral therapy for insomnia delivered by telemedicine is as effective as face-to-face delivery. Results of a randomized controlled non-inferiority trial show that both delivery methods were equally effective at improving sleep outcomes measured by sleep diaries, reducing self-reported […]
